Pulmonary: Page 9

FDA approves IPF drug therapy nerandomilast
It becomes the first new treatment in more than a decade for the severe lung condition.
October 9, 2025
IPF medical logo showing stylized human lungs with cellular cluster
AI-driven CT scan predicts lung disease outcomes at one year
The analysis can identify high-risk patients of fibrotic progression to initiate earlier treatment intervention.
October 6, 2025
Two professional men in business attire, one in a suit and tie, one in casual wear
Scientists propose ‘small lung syndrome’ category
The unique chronic lung condition impacts people with impaired lung function that differs from obstructive respiratory diseases.
October 3, 2025
Transparent medical x-ray showing human lungs in red against skeletal chest structure
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2026 to 2035.
July 21, 2026
Pulmonary drug market forecast
Final trial data show significant benefits of sotatercept
The biologic drug helps reduce symptoms and slow progression of PH when treated early.
October 2, 2025
Healthcare professional examining older patient with stethoscope in medical office
A new outlook on lung scarring
Pain-detecting nerve cells also regulate inflammation and have bearing on pulmonary fibrosis.
September 25, 2025
3D scientific visualization with orange and green organic shapes amid grayscale structures
IL-10’s big role in pulmonary fibrosis
New research sheds light on the significance of the small protein in preventing lung inflammation.
September 25, 2025
Two researchers standing in a laboratory workspace with shelves of boxes
Sponsored
Pulmonary fibrosis insight
Ascend Media
The 2026 report provides global pipeline therapies in various clinical trial stages.
August 10, 2026
Pulmonary fibrosis insight
Pulmonary foam cells contribute to long-COVID
The unique association may help researchers better understand prevention therapies for lasting damage.
September 18, 2025
High magnification showing large rounded alveolar macrophages showing foamy cytoplasm and some anthracotic pigment granules.
Phase 3 trial of efzofitimod falls short of primary endpoint
aTyr Pharma shared the results but affirmed it is not the end of the road for the developmental drug.
September 17, 2025
Clear spirometry device with green, yellow, and red balls measuring lung capacity or respiratory function
IFITM3 drives SCLC immunotherapy response
The protein serves as a key indicator of how a patient with small cell lung cancer will react to current treatments.
September 10, 2025
Patient in gray sweater receiving medical care from a healthcare professional
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2026 to 2035.
July 21, 2026
Pulmonary drug market forecast
Peeling back the layers of pulmonary fibrosis
Exploration of the disease in early stages sheds light on initial chain reaction and inevitable feedback loop.
September 9, 2025
Scientist in white lab coat working with scientific equipment in sterile laboratory
Fresh understanding of African Americans’ sensitivity to lung cancer
Data shed light on some of the genetic sources behind the predisposition.
September 4, 2025
Older woman in white sweater speaking with healthcare professional during consultation
ALA launches new pulmonary fibrosis support program
In connection with Pulmonary Fibrosis Awareness Month this September, the free resource can help people living with or caring for those with PF.
September 3, 2025
Yellow lungs icon for Pulmonary Fibrosis Awareness Month in September
Previous Page
Page 9 of 29
Next Page
Most Popular
Is there a ‘window of opportunity’ for biologic treatment in severe asthma?
FDA approves study of inhaled stem cell therapy for COPD
Common cold: There may be a vaccine for that
Semaglutide significantly lowers asthma, COPD attacks
Novel inhaled treatment for COPD shows promise in clinical trial
MRI reduces cognitive failure, adverse events in SCLC